<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601040</url>
  </required_header>
  <id_info>
    <org_study_id>JSEPI-004</org_study_id>
    <nct_id>NCT02601040</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines</brief_title>
  <official_title>Phase IV Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine in Health Chinese Children and Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Province Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to evaluate the safety and immunogenicity of
      Immunogenicity of Inactivated and Live Attenuated Hepatitis A Vaccines for healthy Chinese
      people.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of hepatitis A antibody concentration</measure>
    <time_frame>37 months</time_frame>
    <description>Changes of anti Hepatitis A antibody geometric mean concentrations at pre-vaccination, month 1,12, 24, 36, and 1 months after the booster vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Compare incidence of all the solicited events(AEs), unsolicited AEs and serious AEs within 28 days post-vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13500</enrollment>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Attenuated Hepatitis A Vaccine, H2 Strain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated Hepatitis A Vaccine, Lu8 Strain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A Meningococcal Polysaccharide vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Attenuated Hepatitis A Vaccine, H2 Strain</intervention_name>
    <description>6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-16 years \6.50 lgCCID50/ml in adults aged 17 up to 65 years old</description>
    <arm_group_label>Attenuated Hepatitis A Vaccine, H2 Strain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Hepatitis A Vaccine, Lu8 Strain</intervention_name>
    <description>320EU/Vial in babies aged 18-35 months \320EU/Vial in children aged 3-16 years \640EU/Vial in adults aged 17 up to 65 years old\boost at month 6\two-dose</description>
    <arm_group_label>Inactivated Hepatitis A Vaccine, Lu8 Strain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group A Meningococcal Polysaccharide vaccine</intervention_name>
    <description>30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old</description>
    <arm_group_label>Group A Meningococcal Polysaccharide vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only subjects fulfilling all of the following criteria will be eligible for the study:

          -  People aged from 18 months to 65 years old.

          -  The subjects or subjects' guardians are able to understand and sign the informed
             consent

          -  The subjects or subjects' guardians allow to comply with the requirements of the
             protocol

          -  Subjects with temperature &lt;=37.0°C on axillary setting

          -  The subjects have signed informed consent already

        Exclusion Criteria:

          -  Subjects will not be eligible for the study if any of the following criteria is met:

          -  Subject who has a medical history of serious disease including Tumor, autoimmune
             disease, progressive atherosclerosis diseases or complications of diabetes, chronic
             obstructive pulmonary disease (copd), kidney disease, congestive heart failure etc.

          -  Have a history of neurological symptoms or signs

          -  Have medical history or family history relating to allergies, seizures, epilepsy,
             brain and spirit etc.

          -  Suffering from serious chronic diseases

          -  Suffering from known or suspected of diseases including respiratory diseases, acute
             infection , mothers have HIV infection, cardiovascular disease, severe hypertension,
             skin diseases, malignant tumor

          -  Allergic to any ingredient in research, history of allergies to any vaccination
             (always), especially for people allergic to high protein food like eggs and milk

          -  Any prior known or suspected damage or abnormal immune function. As for patients who
             are treated with immune inhibitors or immune enhancer medicine, accept with
             immunoglobin, blood products and plasma extraction within 3 months

          -  Any prior diseases including human immunodeficiency virus infection or related

          -  Bleeding constitution or prolong bleeding time situation

          -  Accept hepatitis A vaccination within a month

          -  Received vaccines, other immune globulin, any research drug injections in the past 4
             weeks

          -  People who had any acute illness, needed systemic antibiotics or antiviral treatment
             in the past 7 days

          -  Caught a fever with axillary temperature 38°C or higher in past 3 days

          -  Take part in another clinical researchers

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent

          -  Pregnancy test result is positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingsi Yang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institude of Medical Biology, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fubao Ma</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiangming Sun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institude of Medical Biology, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guodong Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Biology -Chinese Academy of Medical Sciences</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Hepatitis A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

